Pulmonary toxicity of cyclophosphamide: a 1-year study

Area of Science:

• Pulmonary toxicology
• Experimental pathology
• Drug-induced lung injury

Background:

• Cyclophosphamide is a widely used chemotherapy agent.
• Chemotherapy can cause significant side effects, including lung damage.
• Understanding the long-term effects of cyclophosphamide on lung tissue is crucial for patient management.

Purpose of the Study:

• To investigate the chronic pulmonary effects of a single cyclophosphamide dose in mice.
• To characterize the temporal development of cyclophosphamide-induced lung lesions.
• To assess the functional and biochemical changes in the lungs over a one-year period.

Main Methods:

• Male BALB/c mice received a single intraperitoneal injection of cyclophosphamide (100 mg/kg).
• Lung tissues were analyzed for histological changes (macrophages, fibrosis) at various time points up to 52 weeks.
• Hydroxyproline content was measured to quantify fibrosis.
• In vivo pressure-volume curves and total lung volumes were assessed one year post-treatment.

Main Results:

• Cyclophosphamide induced progressive intraalveolar foamy macrophage accumulation and diffuse interstitial fibrosis over 52 weeks.
• Hydroxyproline levels were significantly elevated in treated lungs compared to controls.
• One year after treatment, lungs showed reduced compliance (shifted pressure-volume curves) and decreased total lung volume.

Conclusions:

• A single cyclophosphamide administration results in persistent and worsening pulmonary lesions.
• The observed lung damage includes both cellular infiltration and fibrotic changes.
• Cyclophosphamide-induced pulmonary toxicity is an irreversible process with significant functional consequences.